Tính an toàn và các phản ứng khi tiêm vắc xin covid-19 (Cập nhật đến ngày 29/4/2022)
- Thứ sáu - 29/04/2022 01:01
- |In ra
- |Đóng cửa sổ này
Ảnh hưởng của COVID-19 đã thúc đẩy nhiều nỗ lực trên toàn cầu trong việc tìm hiểu, phát triển và cung cấp các loại vắc-xin mới để kiểm soát đại dịch đang hoành hành. Đến tháng 6/2020, ước tính hàng trăm các loại vắc-xin thử nghiệm được nghiên cứu để đối phó với sự tàn phá do chủng virus mới gây ra. Cục Thông tin khoa học và công nghệ quốc gia xin giới thiệu một số bài nghiên cứu đã được xuất bản chính thức và các bài viết được chấp nhận đăng trên những cơ sở dữ liệu học thuật chính thống. Những nghiên cứu công bố trước đó trong năm 2022 được tổng hợp tại đường link cuối bài.
1. Wiley
1. Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy
Eugenio Milano, Aurelia Ricciardi, Raffaella Casciaro, Elisabetta Pallara, Elda De Vita, Davide F. Bavaro, Angela Maria Vittoria Larocca, Pasquale Stefanizzi, Silvio Tafuri, Annalisa Saracino
First published: 01 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27629
2. Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines
Julia R. Hirsiger, Maria Martinez, Dimitrios A. Tsakiris, Micol G. Cittone, Lukas Graf, Johannes Oldenburg, Behnaz Pezeshkpoor, Mike Recher, Jens Mueller, Bernhard Gerber, Christoph T. Berger
First published: 02 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.15665
3. Fulminant myocarditis after the second dose of COVID-19 mRNA vaccination
Akihiro Oka, Yuya Sudo, Toru Miyoshi, Masatomo Ozaki, Yuta Kimura, Wataru Takagi, Satoko Ugawa, Tomoaki Okada, Kazumasa Nosaka, Masayuki Doi
First published: 07 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/ccr3.5378
4. Structural Insights into the Substrate Binding Site of Main Protease for the Structure-Based COVID-19 Drug Discovery
Rohoullah Firouzi, Mitra Ashouri, Mohammad Hossein Karimi-Jafari
First published: 04 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/prot.26318
5. Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice
Ning Luan, Yunfei Wang, Han Cao, Kangyang Lin, Cunbao Liu
First published: 02 February 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27637
6. Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients
Ahmet Murt, Mehmet R. Altiparmak, Dogukan Ozbey, Serkan F. Yalin, Serap Sert Yadigar, Ridvan Karaali, Bekir Kocazeybek, Nese Saltoglu, Meltem Pekpak, Muveddet R. Ataman
Seminars in DialysisEarly View
First published: 06 January 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1111/sdi.13049
7. Review of selected animal models for respiratory coronavirus infection and its application in drug research
Shengle Qin, Runfeng Li, Zhaoguang Zheng, Xuxin Zeng, Yutao Wang, Xinhua Wang
Journal of Medical Virology
First published: 13 March 2022
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27718
2. Sciencedirect
1. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Cell, 6 January 2022, Volume 185, Issue 3 (Cover date: 3 February 2022), Pages 457-466.e4
Wilfredo F. Garcia-Beltran, Kerri J. St. Denis, Alejandro B. Balazs
https://www.sciencedirect.com/science/article/pii/S0092867421014963/pdfft?md5=4e51a7f75166bfa5590194a4b26c59a7&pid=1-s2.0-S0092867421014963-main.pdf
2. Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey
Psychiatry Research, 7 December 2021, Volume 307 (Cover date: January 2022), Article 114329
Mara Eyllon, Alexander P. Dang, Samuel S. Nordberg
https://www.sciencedirect.com/science/article/pii/S0165178121006247/pdfft?md5=d74f54e7eb8702017665fec319b3d48f&pid=1-s2.0-S0165178121006247-main.pdf
3. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα
Gastroenterology, 28 October 2021, Volume 162, Issue 2 (Cover date: February 2022), Pages 454-467
Hadar Edelman-Klapper, Eran ZittanIris Dotan
https://www.sciencedirect.com/science/article/pii/S001650852103701X/pdfft?md5=05c3c423f2828b4dc7849cf1fd4eb27b&pid=1-s2.0-S001650852103701X-main.pdf
4. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
The Lancet Infectious Diseases, 15 September 2021, Volume 22, Issue 2 (Cover date: February 2022), Pages 196-208
ShengLi Xia, YunTao Zhang, XiaoMing Yang
https://www.sciencedirect.com/science/article/pii/S147330992100462X/pdfft?md5=e55093795ec77e9f695924db05df682d&pid=1-s2.0-S147330992100462X-main.pdf
5. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 5 February 2022, Volume 16, Issue 2 (Cover date: February 2022), Article 102424
Awadhesh Kumar Singh, Sanjeev Ratnakar Phatak, Arvind Sharma
https://www.sciencedirect.com/science/article/pii/S1871402122000388/pdfft?md5=596f6d6dd251713312dfdcb498f5b0d6&pid=1-s2.0-S1871402122000388-main.pdf
6. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
The Lancet, 23 December 2021, Volume 399, Issue 10321 (Cover date: 15–21 January 2022), Pages 237-248
Scott A Halperin, Lingyun Ye, Tao Zhu
https://www.sciencedirect.com/science/article/pii/S0140673621027537/pdfft?md5=35bcee73c438d4c39c42345169e02f83&pid=1-s2.0-S0140673621027537-main.pdf
7. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
International Journal of Infectious Diseases, 17 November 2021, Volume 114 (Cover date: January 2022), Pages 252-260
Caifang Zheng, Weihao Shao, Weidong Zhang
https://www.sciencedirect.com/science/article/pii/S1201971221008572/pdfft?md5=e2ba7e1d5efdf23657a1b0f1b02f3e45&pid=1-s2.0-S1201971221008572-main.pdf
8. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Biomedicine & Pharmacotherapy, 10 December 2021, Volume 146 (Cover date: February 2022), Article 112527
Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Nima Rezaei
https://www.sciencedirect.com/science/article/pii/S0753332221013147/pdfft?md5=ce3bc6bdcaecb8f7425322636edca50f&pid=1-s2.0-S0753332221013147-main.pdf
9. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Clinical Microbiology and Infection, 27 October 2021, Volume 28, Issue 2 (Cover date: February 2022), Pages 202-221
Thibault Fiolet, Yousra Kherabi, Nathan Peiffer-Smadja
https://www.sciencedirect.com/science/article/pii/S1198743X21006042/pdfft?md5=e64467d7b2f863ce462791b810a1310b&pid=1-s2.0-S1198743X21006042-main.pdf
10. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: an interim report
Vaccine, Available online 8 February 2022, In press, journal pre-proof
Taisei Masuda, Kyoko Murakami, Mitsuhiro Mori
https://www.sciencedirect.com/science/article/pii/S0264410X22001645/pdfft?md5=a7157805251e5bc66fd6c2afcb518b7c&pid=1-s2.0-S0264410X22001645-main.pdf
3. Springer
1. A Modern Perspective on Vaccinating Healthcare Service Providers in India: A Narrative Review
Mallavalli Surendranath, Ravi Wankhedkar, Jayesh Lele… in Infectious Diseases and Therapy (2022)
https://link.springer.com/content/pdf/10.1007%2Fs40121-021-00558-9.pdf
2. Global research activity on mathematical modeling of transmission and control of 23 selected infectious disease outbreak
Waleed M. Sweileh in Globalization and Health (2022)
https://link.springer.com/content/pdf/10.1186%2Fs12992-022-00803-x.pdf
3. Understanding and attenuating pandemic-related disruptions: a plan to reduce inequalities in child development
Sylvana M. Côté, Marie-Claude Geoffroy… in Canadian Journal of Public Health (2022)
https://link.springer.com/content/pdf/10.17269%2Fs41997-021-00584-7.pdf
4. COVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit
Navin Kumar, Isabel Corpus, Meher Hans, Nikhil Harle, Nan Yang… in BMC Public Health (2022)
https://link.springer.com/content/pdf/10.1186%2Fs12889-022-12824-7.pdf
5. A review of the safety and efficacy of current COVID-19 vaccines
Zehong Huang, Yingying Su, Tianying Zhang, Ningshao Xia in Frontiers of Medicine (2022)
https://link.springer.com/content/pdf/10.1007%2Fs11684-021-0893-y.pdf
6. Sentiment analysis and topic modeling for COVID-19 vaccine discussions
Hui Yin, Xiangyu Song, Shuiqiao Yang, Jianxin Li in World Wide Web (2022)
https://link.springer.com/content/pdf/10.1007%2Fs11280-022-01029-y.pdf
7. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic
Yiming Shao, Yingqi Wu, Yi Feng, Wenxin Xu, Feng Xiong… in Frontiers of Medicine (2022)
https://link.springer.com/content/pdf/10.1007%2Fs11684-021-0913-y.pdf
8. Vaccination With Routine Childhood Vaccines and Severity of COVID-19 Among Children in Delhi
Dr Madan Mohan Majhi, Amod Laxmikant Borle, Panna Lal, Meenu Meena… in Indian Pediatrics (2022)
https://link.springer.com/content/pdf/10.1007%2Fs13312-022-2445-1.pdf
9. AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
Syed B. Ali, Griffith Perkins, Dongjae Ryoo… in Allergy, Asthma & Clinical Immunology (2022)
https://link.springer.com/content/pdf/10.1186%2Fs13223-022-00665-3.pdf
4. Pubmed
1. COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies.
Declercq J, Tobback E, Vanhee S, De Ruyck N, Gerlo S, Gevaert P, Vandekerckhove L.
Allergy. 2022 Jan;77(1):304-307. doi: 10.1111/all.15101. Epub 2021 Sep 29.
PMID: 34543444
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653144/pdf/ALL-9999-0.pdf
2. Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022.
Downes KJ, Statler VA, Orscheln RC, Cousino MK, Green M, Michaels MG, Muller WJ, Sharma TS, Danziger-Isakov LA, Ardura MI.
J Pediatric Infect Dis Soc. 2022 Feb 23;11(2):43-54. doi: 10.1093/jpids/piab098.
PMID: 34734268
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689907/pdf/piab098.pdf
3. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe.
Wagner R, Meißner J, Grabski E, Sun Y, Vieths S, Hildt E.
Allergy. 2022 Jan;77(1):72-82. doi: 10.1111/all.14868. Epub 2021 May 21.
PMID: 33887070
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251031/pdf/ALL-9999-0.pdf
4. Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.
Park H, Park MS, Seok JH, You J, Kim J, Kim J, Park MS.
J Microbiol. 2022 Mar;60(3):308-320. doi: 10.1007/s12275-022-1598-x. Epub 2022 Mar 2.
PMID: 35235179
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890016/pdf/12275_2022_Article_1598.pdf
5. Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
Akgün Ö, Kayaalp GK, Demirkan FG, Çakmak F, Tanatar A, Guliyeva V, Sönmez HE, Ayaz NA.
Vaccine. 2022 Mar 15;40(12):1829-1836. doi: 10.1016/j.vaccine.2022.01.061. Epub 2022 Feb 4.
PMID: 35151508
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813553/pdf/main.pdf
6. Determinants and Variations of COVID-19 Vaccine Uptake and Responses Among Minority Ethnic Groups in Amsterdam, the Netherlands.
Antwi-Berko D, Bakuri AZ, Otabil KB, Kwarteng A.
Front Public Health. 2022 Feb 17;10:761987. doi: 10.3389/fpubh.2022.761987. eCollection 2022.
PMID: 35252081
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891150/pdf/fpubh-10-761987.pdf
7. Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
Lennon RP, Block R Jr, Schneider EC, Zephrin L, Shah A; African American Research Collaborative 2021 COVID Group. Electronic address: henry@africanamericanresearch.us.
Vaccine. 2022 Jan 28;40(4):562-567. doi: 10.1016/j.vaccine.2021.11.097. Epub 2021 Dec 7.
PMID: 34903376
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650809/pdf/main.pdf
8. Covid Vaccine Mandates and Religious Accommodation in Employment.
Rothstein MA.
Hastings Cent Rep. 2022 Jan;52(1):8-9. doi: 10.1002/hast.1294. Epub 2021 Nov 8.
PMID: 34747499
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653090/pdf/HAST-9999-0.pdf
9. Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients.
Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Afsharian M, Saleki K, Barary M, Ebrahimpour S.
Rev Med Virol. 2022 Mar;32(2):e2273. doi: 10.1002/rmv.2273. Epub 2021 Jul 1.
PMID: 34197678
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420499/pdf/RMV-9999-e2273.pdf
10. COVID-19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout.
Dietze PM, Hall C, Price O, Stewart AC, Crawford S, Peacock A, Maher L.
Drug Alcohol Rev. 2022 Feb;41(2):484-487. doi: 10.1111/dar.13399. Epub 2021 Nov 9.
PMID: 34752659
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653113/pdf/DAR-9999-0.pdf
11. Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults 18 years, United States.
Nguyen KH, Anneser E, Toppo A, Allen JD, Scott Parott J, Corlin L.
Vaccine. 2022 Jan 3;40(1):107-113. doi: 10.1016/j.vaccine.2021.11.040. Epub 2021 Nov 18.
PMID: 34852946
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598948/pdf/main.pdf
12. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
Mak WA, Koeleman JGM, van der Vliet M, Keuren F, Ong DSY.
J Infect. 2022 Feb;84(2):171-178. doi: 10.1016/j.jinf.2021.12.003. Epub 2021 Dec 9.
PMID: 34896516
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656179/pdf/main.pdf
13. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination.
Cinotti E, Perrot JL, Bruzziches F, Tognetti L, Batsikosta A, Sorrentino E, Marzano AV, Rubegni P.
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e171-e172. doi: 10.1111/jdv.17806. Epub 2021 Nov 20.
PMID: 34753210
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657533/pdf/JDV-9999-0.pdf
14. Acute macular neuroretinopathy following COVID-19 vaccination.
Bøhler AD, Strøm ME, Sandvig KU, Moe MC, Jørstad ØK.
Eye (Lond). 2022 Mar;36(3):644-645. doi: 10.1038/s41433-021-01610-1. Epub 2021 Jun 22.
PMID: 34158652
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217204/pdf/41433_2021_Article_1610.pdf
15. Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
Mewhirter J, Sagir M, Sanders R.
Vaccine. 2022 Mar 15;40(12):1783-1789. doi: 10.1016/j.vaccine.2022.02.011. Epub 2022 Feb 7.
PMID: 35164989
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832389/pdf/main.pdf
Các công bố về COVID-19 trước thời gian trên:
Cập nhật các công bố về COVID-19 từ ngày 16/4 đến ngày 22/4/2022
Cập nhật các công bố về COVID-19 từ ngày 9/4 đến ngày 15/4/2022
Cập nhật các công bố về COVID-19 từ ngày 4/4 đến ngày 8/4/2022
Cập nhật các công bố về COVID-19 từ ngày 26/3 đến ngày 1/4/2022
Cập nhật các công bố về COVID-19 từ ngày 18/3 đến ngày 25/3/2022
Cập nhật các công bố về COVID-19 từ ngày 11/3 đến ngày 18/3/2022
Cập nhật các công bố về COVID-19 từ ngày 4/3 đến ngày 11/3/2022
Cập nhật các công bố về COVID-19 từ ngày 25/3 đến ngày 4/3/2022
Cập nhật các công bố về COVID-19 từ ngày 18/2 đến ngày 25/2/2022
Cập nhật các công bố về COVID-19 từ ngày 11/2 đến ngày 18/2/2022
Cập nhật các công bố về COVID-19 từ ngày 4/2 đến ngày 11/2/2022
Cập nhật các công bố về COVID-19 từ ngày 21/1 đến ngày 28/1/2022
Cập nhật các công bố về COVID-19 từ ngày 14/1 đến ngày 21/1/2022
Cập nhật các công bố về COVID-19 từ ngày 7/1 đến ngày 14/1/2022
Cập nhật các công bố về COVID-19 từ ngày 1/1 đến ngày 7/1/2022
Nguồn: Cục Thông tin khoa học và công nghệ quốc gia, 29/4/2022